2015 med tech R&D budget: $1.244 billion
Change from 2014 budget ($1.134 billion): 9%
Percent of 2015 segment sales ($11.24 billion): 10%
Roche ($RHHBY) relies on diagnostics to get its med tech engine running. This past year has included deals and product launches that help the company maintain dominance in a crowded field.
Roche recently got FDA approval for its liquid biopsy companion diagnostic for the cancer drug Tarceva. The news marked a big win for Roche, which faces a slew of competition in the liquid biopsy field.
But liquid biopsy is only part of Roche’s overall strategy. The company has also turned to dealmaking to ramp up R&D. In February 2015, Roche said it would shell out $1.2 billion for a majority share in Foundation Medicine ($FMI).
As part of the deal, Roche vowed to funnel $150 million over the next 5 years into a “broad R&D collaboration” with Foundation. The deal was meant to speed up product development and expand the companies’ global marketing efforts.
In August, Roche struck a couple of deals to flesh out its portfolio. The company snatched up microbiology firm GeneWeave BioSciences to boost its offerings for drug-resistant bacteria testing. It also acquired Kapa Biosystems to get its hands on the company’s next-generation sequencing products and build out its NGS portfolio.
Roche scores first liquid biopsy FDA approval with Tarceva companion Dx
Roche launches home testing device for anticoagulant patients in Europe
Roche launches rapid HIV, hep C tests in Europe
Roche's M&A party rages on with Kapa Biosystems deal
Roche shells out up to $425M for superbug testing outfit